Title: Salivary IgG antibody response to SARS-CoV-2 as a non-invasive assessment of immune response. Differences between vaccinated children and adults

Author names and affiliations: María Noel Badano[1], Irene Keitelman[1], Matías Javier Pereson[1], Natalia Aloisi[2], Florencia Sabbione[1], Patricia Baré[1,2]

[1] Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Academia Nacional de Medicina. Postal address: J.A. Pacheco de Melo 3081, CABA 1425, Buenos Aires, Argentina.
[2] Instituto de Investigaciones Hematológicas (IIHEMA), Academia Nacional de Medicina. Postal address: J.A. Pacheco de Melo 3081, CABA 1425, Buenos Aires, Argentina.

Corresponding author: María Noel Badano, Laboratorio de Patogenia de Infecciones Virales, Instituto de Medicina Experimental (IMEX)-CONICET, Academia Nacional de Medicina, J.A. Pacheco de Melo 3081, CABA 1425, Buenos Aires, Argentina. E-mail: noebadano@yahoo.com.ar. Telephone number: +5491167586135. ORCID identifier: 0000-0002-0358-7738.

Short title: Higher salivary IgG SARS-CoV-2 levels in vaccinated children

Data availability statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.

Funding/Support: This study was supported by a grant from CONICET (PIP 11220210100378CO).

Conflict of Interest Disclosure: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Ethics Statement: This study was approved by the Academia Nacional de Medicina Ethics Committee.

Consent Statement: Written informed consent was obtained from adult participants and from parents for children participants.

Abbreviations: binding antibody units (BAU) per mL (BAU/mL), geometric mean concentrations (GMC), 95% confidence intervals (95% CI).

Abstract

Studies comparing systemic and salivary antibody responses against SARS-CoV-2 between children and adults show conflicting results. Furthermore, it is still unclear whether salivary antibody testing could be a non-invasive approach to evaluate the humoral immune response. Our results showed that salivary IgG antibody response against SARS-CoV-2 largely reflects the systemic response in vaccinated adults. Salivary and systemic antibody concentrations were higher in vaccinated adults who had been infected, received schedules including mRNA-based vaccines, had more exposures, and a shorter time since last exposure. Salivary antibody detection was associated with schedules including mRNA-based vaccines, time since last exposure, and systemic antibody concentrations.

Vaccinated children showed higher salivary antibody concentrations than adults. This difference remained when comparing antibody levels between children and adults under equal conditions (vaccination schedules, number of exposures, time from last exposure, COVID-19 history). Age and schedules including mRNA-based vaccines were associated with salivary antibody levels in a multivariable linear regression analysis ($p < 0.0001$).

Salivary antibody determination against SARS-CoV-2 could be a non-invasive assessment of the short-term immune response in adults with multiple exposures.

Furthermore, the stronger salivary antibody response in children suggests that local immune protection may differ between children and adults, contributing to different outcomes.

Keywords

SARS-CoV-2; Salivary IgG antibody response; Systemic IgG antibody response; vaccines; children.

Introduction

While several advances have been made in the understanding of SARS-CoV-2 infection and its associated pathology, certain aspects related to the immune response remain uncertain. Furthermore, the lower availability of blood samples from children coupled with the late administration of COVID-19 vaccines in this population led to less knowledge about their immune response following infection and vaccination in comparison to adults.

It is still debatable whether children and adults show similar systemic humoral immune responses against SARS-CoV-2 after infection and vaccination. Studies have reported similar [1, 2], lower [3, 4] or stronger and longer-lasting [5, 6] systemic antibody responses to SARS-CoV-2 infection in children than adults. There are also conflicting results regarding antibody responses following vaccination, with studies showing higher [6, 7], similar [8-10] or lower [4] SARS-CoV-2-specific antibody levels in children compared to adults.

Information about the mucosal immune response against SARS-CoV-2 in children is limited. Using saliva-based tests, the prevalence of salivary anti-SARS-CoV-2 IgG antibodies in unvaccinated and vaccinated children has been studied [11-13], further showing that salivary antibody levels increase following infection or household contact exposure [12, 14] and vaccination [13]. However, studies comparing salivary antibody responses against SARS-CoV-2 between children and adults have yielded contradictory results, showing higher [15] or lower [4] salivary antibody levels in children than in adults.

On the other hand, results from studies comparing systemic and salivary humoral immune responses to SARS-CoV-2 are inconsistent. While several studies have shown a positive correlation between systemic and salivary anti-SARS-CoV-2 IgG antibody levels in both adults [16-18] and children [11, 15], other studies have shown a weak correlation [19, 20]. We have also previously shown that SARS-CoV-2 breakthrough infections in vaccinated adults boost antibody levels not only in the blood but also in the salivary compartment [21]. Therefore, although several studies have

demonstrate the validity of assessing specific salivary antibodies as indicators of seroconversion

after natural infection or vaccination [16-18, 22-23], it remains unclear whether saliva could be

suitable as a non-invasive alternative to blood for monitoring antibodies against SARS-CoV-2.

In this work we investigated and compared the systemic and salivary IgG antibody responses

against SARS-CoV-2 in vaccinated adults, to analyze whether the determination of salivary

antibodies against SARS-CoV-2 could be a non-invasive approach to evaluate the humoral immune

response following infection or vaccination. Salivary antibody levels were also compared between

vaccinated children and adults to analyze whether the specific humoral immune response differed

within the salivary compartment.

Materials and methods

Study Design, Participants and Samples

Since the beginning of the COVID-19 pandemic, we conduct an observational prospective cohort

study to investigate the humoral immune response against SARS-CoV-2 after infection and

vaccination. Adult participants were healthcare workers from our institution, the Academia

Nacional de Medicina. Child participants were sons and daughters of healthcare workers and their

schoolmates. SARS-CoV-2 diagnoses were conducted in adults and children with COVID-19

symptoms and in some household members without symptoms. If a household member tested

positive for SARS-CoV-2 and no isolation measures were taken, all other household members were

considered exposed (household contacts), except those who were subsequently diagnosed. SARS-

CoV-2 infection was confirmed by RT-PCR in nasopharyngeal/oropharyngeal swabs or in saliva

samples. Children and adults were monitored and information regarding demographic characteristic

(date of birth, sex), vaccination (dates and schedules), COVID-19 history (date and presence of

symptoms in positive cases and household contacts) was completed in an online questionnaire by

adults and parents.

In this study, blood and saliva sample pairs ($n = 101$) from adults who had received the primary

vaccination schedule and a booster dose collected between December 2021-July 2022 were

included. Saliva samples ($n = 86$) from children up to 18 years old who had received two or three

vaccine doses collected between February-August 2022 were also included. The samples included

were obtained from uninfected adults and children, as well as from those who became infected or

were household contacts at any stage of vaccination. All subjects with confirmed past SARS-CoV-2

infection had mild disease based on the World Health Organization classification [24]. Information

regarding demographic characteristic, COVID-19 history, vaccination schedules, number of

exposures (through vaccination, infection or household contact exposure) and time between last

exposure and sample collection is detailed in Table 1. Vaccines from the same platform were

administered on similar dates and with similar interval time between doses. This study was

approved by the Academia Nacional de Medicina Ethics Committee. Written informed consent was

obtained from adult participants and from parents for children participants.

Sample collection and processing

Plasma or serum samples were obtained immediately after centrifugation of the peripheral blood

and stored in aliquots at $-20°C$ until use. For saliva sampling, individuals provided their first saliva

of the day by spitting into a tube, ensuring they had not consumed any food or drink, brushed their

teeth, or engaged in other activities prior to collection that could introduce variability. Saliva

samples were centrifuged at 17,000 x g for 10 min (4°C) and the supernatant was stored at $-20°C$

until use.

SARS-CoV-2 Antibody ELISA

Detection of anti-spike SARS-CoV-2 IgG antibodies in both blood and saliva was performed by

ELISA (COVIDAR-IgG, Laboratorios Lemos S.R.L, Buenos Aires, Argentina). The assay plates

are coated with a purified mixture of the spike protein and the receptor binding domain (RBD) of

SARS-CoV-2 from the original Wuhan viral variant (GenBank: MN908947). Determination of

specific antibodies in blood was performed following the manufacturer's instructions [21].

Assessment of salivary antibodies was performed with the conditions we had previously established

[21]. Basically, salivary IgG anti-spike antibodies were determined as plasma ones, without

performing the first sample dilution. As pre-pandemic samples were unavailable, negative controls

comprised PCR-negative saliva samples from early stages of the pandemic obtained before

vaccination. Antibody concentrations in binding antibody units (BAU) per mL (BAU/mL) were

obtained by interpolating the OD 450 nm values of the samples into a calibration curve performed

with the provided standard (400 BAU/mL). Each sample was properly diluted to fit an OD 450 nm

within the linear range of the calibration curve.

Statistical Analysis

Data analyses were performed using the GraphPad 10.2.3 Prism software (GraphPad Software, San

Diego, CA, USA). Geometric mean concentrations (GMC) of specific antibody levels with 95%

confidence intervals (95% CI) were calculated. Antibody levels were analyzed according to

variables previously reported to be associated with systemic anti-SARS-CoV-2 IgG antibody levels

(age, sex, number of exposures, vaccination schedules, SARS-CoV-2 infection and time between

most recent antigen exposure and sample collection). Antibody levels between two groups were

compared with Mann–Whitney test. A multivariate linear regression model was performed

including these variables as independent variables and salivary antibody levels as the dependent

variable. The linear regression coefficients (β) with 95% CI were calculated. The Spearman

coefficient of rank correlation was used to assess the correlation between specific salivary and

blood antibodies. In all cases, a value of $p < 0.05$ was considered indicative of a significant

difference.

Results

IgG specific salivary and blood antibody responses in vaccinated adults

Specific antibodies were detected in 100% of blood samples (GMC BAU/mL, 95% CI: 3154,

2461−4043) and in 82% of saliva samples (GMC BAU/mL, 95% CI: 67.0, 42.8−104.7). Subjects

with higher systemic antibody levels (≥GMC: 3154 BAU/mL) also showed higher salivary antibody

concentrations compared to those with lower systemic antibody levels (GMC BAU/mL, 95% CI,

Saliva: 156.8, 92.7−265.2 *vs* 24.2, 11.1−52.7; $p < 0.001$). Furthermore, higher systemic antibody

levels were found in subjects with detectable salivary antibodies compared to those without

detectable salivary antibodies (GMC BAU/mL, 95% CI, Blood: 3841, 2979−4952 *vs* 1316,

701.1−2469; $p < 0.01$) (Figure 1A-D, white and black shapes). Specific antibody levels in blood and

saliva were positively correlated ($r = 0.5$, $p < 0.0001$).

Therefore, we analyzed how variables previously reported to be associated with systemic anti-

SARS-CoV-2 IgG antibody levels (see Materials and methods for details), relate to antibody levels

in both the blood and the salivary compartment. Similar results were observed in the blood and in

the salivary compartment. The results of the variables where significant differences in antibody

levels were observed are shown. As similar results were observed among subjects who received one

or two doses of mRNA-based vaccines, they were combined into a single group (non-mRNA +

mRNA (3d)) for results presentation. Levels of anti-spike SARS-CoV-2 IgG antibodies were higher

in subjects who received three doses of schedules that included mRNA-based vaccines (non-mRNA

+ mRNA (3d)) compared to those in individuals who received three doses of schemes not including

mRNA-based vaccines (non-mRNA (3d)) (GMC BAU/mL, 95% CI, Blood: 6335, 3990−10058 *vs*

2494, 1875−3318; *p* < 0.01; Saliva: 183.3, 106.5−315.6 *vs* 47.2, 27.1−82.2; *p* < 0.01) (Figure 1A).

Subjects with a greater number of exposures to SARS-CoV-2 antigens showed higher antibody

concentrations than those with a lower number of exposures (GMC BAU/mL, 95% CI, Blood:

5586, 4237−7365 *vs* 1615, 1162−2245; *p* < 0.0001; Saliva: 99.0, 52.6−186.4 *vs* 43.2, 23.5−80.0; *p* <

0.01) (Figure 1B). Antibody concentrations decreased as the interval time between last exposure

and sample collection increased (GMC BAU/mL, 95% CI, Blood: 5448, 4087−7263 *vs* 1847,

1305−2614; *p* < 0.0001; Saliva: 179.3, 113.3−283.7 *vs* 22.0, 11.1−43.5; *p* < 0.0001) (Figure 1C).

Adults who had been infected with SARS-CoV-2 showed higher antibody levels than uninfected

subjects (GMC BAU/mL, 95% CI, Blood: 5398, 4125−7064 *vs* 1920, 1337−2757; *p* < 0.0001;

Saliva: 106.1, 53.3−211.4 *vs* 44.9, 24.8−81.2; *p* < 0.01) (Figure 1D).

Using Fisher's exact test, detection of specific antibodies in saliva was associated with schedules

including mRNA-based vaccines (*p* < 0.05; OR=7.8) (Figure 1A), the time between last exposure

and sample collection (*p* < 0.001; OR=7.8) (Figure 1C) and systemic antibody concentrations (*p* <

0.01; OR=7.1) (Figure 1A-D).

Comparison of IgG specific salivary antibody responses between vaccinated children

and adults

Considering all samples, children showed higher salivary antibody concentrations compared to

adults (GMC: 104.0 BAU/mL, 95% CI: 58.7−184.1 *vs* 66.0 BAU/mL, 95% CI: 42.8−104.7; *p* <

0.05). Therefore, antibody levels were compared between adults and children who shared the same

conditions (vaccination schedules, number of exposures, time from last exposure, COVID-19

history). Children who received three doses of mRNA vaccines (mRNA (3d)) (GMC: 486.0

BAU/mL; 95% CI: 220.7–1069) or three doses combining mRNA and non-mRNA-based vaccines

(non-mRNA + mRNA (3d)) (GMC: 1997 BAU/mL; 95% CI: 878.6–4538) showed higher antibody

concentrations than adults who received three doses of schedules including mRNA-based vaccines

($p < 0.01$) (Figure 2A). Salivary antibody titers were higher in children compared to adults who had

the same number of exposures (GMC BAU/mL, 95% CI, 3X: 138.4, 64.3−298.0 vs 43.2, 23.5−80.0;

$p < 0.001$; 4X: 495.3, 178.2–1377 vs 99.0, 52.6–186.4; $p < 0.001$) (Figure 2B). Antibody

concentrations were higher in children compared to adults who had the same interval time (≤58

days) between last exposure and saliva collection (GMC: 396.0 BAU/mL, 95% CI: 185.8−844.1 vs

GMC: 156.3 BAU/mL, 95% CI: 98.0−249.6; $p < 0.01$) (Figure 2C). Children who had been infected

with SARS-CoV-2 showed higher antibody levels than adults who had been infected (GMC

BAU/mL, 95% CI: 732.7, 305.6−1757 vs 106.1, 53.3−211.4) ($p < 0.01$) (Figure 2D). Multivariable

linear regression analysis showed that age ($\beta1$: -20.3, 95% CI: -35.1−-5.5; $p < 0.01$) and schedules

that included mRNA-based vaccines ($\beta2$: 795.3, 95% CI: 277.8−1313; $p < 0.01$) were associated

with salivary antibody levels ($p < 0.0001$).

Discussion

Data from studies comparing antibody responses against SARS-CoV-2 after infection or

vaccination between children and adults are conflicting in blood [1-10] and in the mucosa [4, 15].

On the other hand, as studies comparing systemic and salivary humoral immune responses to

SARS-CoV-2 have yielded contradictory results [11, 15, 16-22], it remains yet to be determined

whether saliva could be used as a non-invasive alternative to blood for the determination of

antibodies against SARS-CoV-2.

In this work, we investigated and compared the systemic and salivary IgG antibody responses

against SARS-CoV-2 in vaccinated adults. Analysis of different variables previously reported to be

related to systemic anti-SARS-CoV-2 IgG antibody levels showed similar results for blood and

saliva. Higher antibody concentrations were observed in both the blood and saliva of vaccinated

adults who had been infected with SARS-CoV-2, received schedules including mRNA-based

vaccines, had more exposures, and a shorter interval time between last exposure and sample

collection. Furthermore, a positive correlation was found between systemic and salivary anti-SARS-

CoV-2 IgG antibody levels, with higher salivary antibody concentrations observed in subjects with

higher systemic antibody levels. However, specific antibodies were detected in 100% of blood

samples and in 82% of saliva samples. Detection of specific salivary antibodies was associated with

schedules that included mRNA-based vaccines, time between last exposure and sample collection,

and systemic antibody concentrations. These results, together with the fact that most subjects

without detectable salivary antibodies showed lower systemic antibody levels, suggest that salivary

antibody detection could depend on variables that influence systemic antibody levels. Therefore,

although our results showed that the salivary immune response against SARS-CoV-2 in vaccinated

adults largely reflects that observed at systemic levels, salivary antibody detection might not be

possible in subjects presenting lower systemic antibody concentrations. This is in agreement with

previous results showing that salivary antibody responses were mainly detected in subjects showing

higher serum antibody levels [25]. However, in our studies, the prevalence of salivary antibodies

was high in both adults (82%) and children (81%) [12], in contrast to previous results in

unvaccinated infected subjects [11, 13, 25] but in agreement with studies in vaccinated subjects [13,

18, 22-23]. This suggests that multiple exposures are likely required to enhance systemic antibody

levels and allow salivary antibody detection.

We also compared salivary antibody concentrations between vaccinated children and adults to

analyze whether specific antibody responses differed within the salivary compartment. Vaccinated

children showed a higher salivary antibody response against SARS-CoV-2 compared to adults. This

difference remained when antibody levels were compared between vaccinated children and adults

who shared the same conditions (vaccination schedules, number of exposures, time from last

exposure, COVID-19 history). Multivariable linear regression analysis showed that age and

schedules including mRNA-based vaccines were associated with salivary anti-SARS-CoV-2 IgG

antibody levels.

The biological and molecular basis for a favorable outcome after SARS-CoV-2 infection in children

compared to adults is not fully understood. Several hypotheses have tried to explain the milder

presentation of the disease in children, including a protective role of pre-existing cross-reactive

antibodies against seasonal coronaviruses, a lower expression of the angiotensin-converting enzyme

2 (ACE2) and a less propensity to develop an exacerbated pro-inflammatory response, among

others [26]. However, the contribution of the antibody response against SARS-CoV-2 to the

favorable outcome in the pediatric population is not entirely clear. In the current work, we showed

that children had higher salivary anti-SARS-CoV-2 IgG antibody concentrations than adults. Given

that mucosal immunity plays a key role in prevention and early defense against infection, being the

entry route for the virus and the site of first encounter with the immune response, it is tempting to

speculate that the stronger salivary antibody response observed in children could help prevent or

limit infection, thus contributing to the favorable outcome observed in the pediatric population.

Although salivary IgG is primarily derived from circulating IgG through transudation [27] and the

salivary IgG response in adults highly reflects the systemic antibody response, it remains to be

determined whether the salivary antibody response in children also similarly reflects that in blood.

Besides, given there is also some local IgG production, it cannot be ruled out that a difference in the

local antibody response mounted may also account to the observed difference in the salivary

antibody response against SARS-CoV-2 between children and adults.

Limitations of this study included the lack of information on the systemic antibody response in

children, which precluded the comparison between systemic and salivary immune responses in

them. The limited availability of saliva samples (especially those from children that were diluted

several times), prevented further investigation on neutralizing and specific IgA antibody responses.

While some reports showed that salivary anti-SARS-CoV-2 IgG antibody levels strongly correlate

with the neutralizing capacities of both serum [18] and saliva [23], knowledge of salivary IgA and

neutralizing antibody responses could also add insights related to the local immune protection in

children and adults. Information about SARS-CoV-2 variants involved in the infections/household

contact exposures and their association with antibody levels was not available. However, most

infections/household contact exposures, both in adults and children, occurred when the only

circulating variant in Argentina was Omicron.

Altogether, our results showed that the salivary IgG antibody response against SARS-CoV-2 largely

reflects the systemic response in vaccinated adults. However, salivary antibodies may not be

detectable in subjects with low systemic antibody levels. Nevertheless, since saliva sampling is non-

invasive and allows self-collection, salivary antibody determination could be performed as an initial

screening to evaluate the antibody response against SARS-CoV-2. Besides, as salivary antibody

response is indicative of the systemic, salivary antibody determination could guide vaccination

strategies by administering booster doses to subjects without detectable salivary antibodies,

allowing them to achieve high systemic antibody levels.

In conclusion, the determination of salivary antibodies against SARS-CoV-2 could be a non-

invasive approach for the evaluation of the short-term immune response in subjects with multiple

exposures, either resulting from vaccination combined with infection or from the administration of

immunogenic vaccination schedules, both in the adult and pediatric population, especially in

settings where blood sampling cannot be performed.

Furthermore, the higher levels of salivary anti-SARS-CoV-2 IgG antibodies observed in children

suggests that local immune protection may differ between children and adults. Whether the stronger

salivary antibody response in children provides improved local immune protection and contributes

to the favorable outcome in the pediatric population warrants further investigation.

Acknowledgments

This study was supported by a grant from CONICET (PIP 11220210100378CO). Some aspects of

this work could not have been fulfilled without the generous contribution of the IIHEMA and the

Academia Nacional de Medicina, who provide financial support to our ongoing research. The

authors thank all the children and adults enrolled in this study for their participation and

collaboration.

Conflict of Interest

The authors declare that they have no conflict of interest.

Author contributions

M.N.B and P.B conceived and designed the study, M.N.B, I.K., M.P, N.A, F.S., and P.B.;

participated in sample and clinical data collection, M.N.B, I.K., F.S., and P.B., performed the

experiments, M.N.B and P.B.; analyzed and interpreted the data., M.N.B. and P.B.; drafted the first

version and wrote the final version of the manuscript. All authors read and approved the final

manuscript version.

References

1.   Weisberg SP, Connors TJ, Zhu Y, Baldwin MR, Lin WH, Wontakal S, et al. Distinct antibody responses to SARS-
CoV-2 in children and adults across the COVID-19 clinical spectrum. Nat Immunol. 2021;22(1):25-31. doi:
10.1038/s41590-020-00826-9.

2.   Toh ZQ, Higgins RA, Do LAH, Rautenbacher K, Mordant FL, Subbarao K, Dohle Ket al. Persistence of SARS-
CoV-2-Specific IgG in Children 6 Months After Infection, Australia. Emerg Infect Dis. 2021;27(8):2233-2235. doi:
10.3201/eid2708.210965.

3.   Hachim A, Gu H, Kavian O, Mori M, Kwan MYW, Chan WH, et al. SARS-CoV-2 accessory proteins reveal
distinct serological signatures in children. Nat Commun. 2022;13(1):2951. doi: 10.1038/s41467-022-30699-5.

4.   Padoan A, Cosma C, Di Chiara C, Furlan G, Gastaldo S, Talli I, et al. Clinical and Analytical Performance of
ELISA Salivary Serologic Assay to Detect SARS-CoV-2 IgG in Children and Adults. Antibodies (Basel). 2024
Jan;13(1):6. doi: 10.3390/antib13010006.

5.   Dowell AC, Butler MS, Jinks E, Tut G, Lancaster T, Sylla P, et al. Children develop robust and sustained cross-
reactive spike-specific immune responses to SARS-CoV-2 infection. Nat Immunol. 2022;23(1):40-49. doi:
10.1038/s41590-021-01089-8.

6.   Kim M, Cheng WA, Congrave-Wilson Z, Marentes Ruiz CJ, Turner L, et al. Comparisons of Pediatric and Adult
SARS-CoV-2-Specific Antibodies up to 6 Months after Infection, Vaccination, or Hybrid Immunity. J Pediatric
Infect Dis Soc. 2024;13(1):91-99. doi: 10.1093/jpids/piad107.

7.   Tawinprai K, Siripongboonsitti T, Porntharukchareon T, Vanichsetakul P, Thonginnetra S, Niemsorn K, et al.
Safety and Immunogenicity of the BBIBP-CorV Vaccine in Adolescents Aged 12 to 17 Years in the Thai
Population: An Immunobridging Study. Vaccines (Basel). 2022 ;10(5):807. doi: 10.3390/vaccines10050807.

8.   Rosa Duque JS, Wang X, Leung D, Cheng SMS, Cohen CA, Mu X, et al. Immunogenicity and reactogenicity of
SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents. Nat Commun. 2022;13(1):3700. doi:
10.1038/s41467-022-31485-z.

9.   Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated COVID-19
vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial.
Lancet Infect Dis. 2022;22(2):196-208. doi: 10.1016/S1473-3099(21)00462-X.

10.   Li G, Cappuccini F, Marchevsky NG, Aley PK, Aley R, Anslow R, et al. Safety and immunogenicity of the
ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2

single-blind, randomised, controlled trial. Lancet. 2022;399(10342):2212-2225. doi: 10.1016/S0140-
6736(22)00770-X.

11. Keuning MW, Grobben M, Bijlsma MW, Anker B, Berman-de Jong EP, Cohen S, et al. Differences in systemic and
mucosal SARS-CoV-2 antibody prevalence in a prospective cohort of Dutch children. Front Immunol.
2022;13:976382. doi: 10.3389/fimmu.2022.976382.

12. Badano MN, Duarte A, Salamone G, Sabbione F, Pereson M, Chuit R, et al. Prevalence of salivary anti-SARS-CoV-
2 IgG antibodies in vaccinated children. Immunology. 2023;169(3):384-387. doi: 10.1111/imm.13656.

13. Conti MG, Piano Mortari E, Nenna R, Pierangeli A, Sorrentino L, Frasca F, et al. SARS-CoV-2-specific mucosal
immune response in vaccinated versus infected children. Front Cell Infect Microbiol. 2024;14:1231697. doi:
10.3389/fcimb.2024.1231697.

14. Thomas AC, Oliver E, Baum HE, Gupta K, Shelley KL, Long AE, et al. Evaluation and deployment of isotype-
specific salivary antibody assays for detecting previous SARS-CoV-2 infection in children and adults. Commun
Med (Lond). 2023;3(1):37. doi: 10.1038/s43856-023-00264-2.

15. Dobaño C, Alonso S, Vidal M, Jiménez A, Rubio R, Santano R, et al. Multiplex Antibody Analysis of IgM, IgA and
IgG to SARS-CoV-2 in Saliva and Serum From Infected Children and Their Close Contacts. Front Immunol.
2022;13:751705. doi: 10.3389/fimmu.2022.751705.

16. Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, et al. Persistence of serum and saliva antibody responses to
SARS-CoV-2 spike antigens in COVID-19 patients. Sci Immunol. 2020;5(52):eabe5511. doi:
10.1126/sciimmunol.abe5511.

17. Pisanic N, Randad PR, Kruczynski K, Manabe YC, Thomas DL, Pekosz A, et al. COVID-19 Serology at Population
Scale: SARS-CoV-2-Specific Antibody Responses in Saliva. J Clin Microbiol. 2020;59(1):e02204-20. doi:
10.1128/JCM.02204-20.

18. Healy K, Pin E, Chen P, Söderdahl G, Nowak P, Mielke S, et al. Salivary IgG to SARS-CoV-2 indicates
seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals. Med.
2022;3(2):137-153.e3. doi: 10.1016/j.medj.2022.01.001.

19. Darwich A, Pozzi C, Fornasa G, Lizier M, Azzolini E, Spadoni I, et al. BNT162b2 vaccine induces antibody release
in saliva: a possible role for mucosal viral protection? EMBO Mol Med. 2022;14(5):e15326. doi:
10.15252/emmm.202115326.

20. Azzi L, Dalla Gasperina D, Veronesi G, Shallak M, Ietto G, Iovino D, et al. Mucosal immune response in
BNT162b2 COVID-19 vaccine recipients. EBioMedicine. 2022;75:103788. doi: 10.1016/j.ebiom.2021.103788.

21. Badano MN, Pereson MJ, Sabbione F, Keitelman I, Aloisi N, Chuit R, et al. SARS-CoV-2 Breakthrough Infections
after Third Doses Boost IgG Specific Salivary and Blood Antibodies. Vaccines (Basel). 2023;11(3):534. doi:
10.3390/vaccines11030534.

22. Ketas TJ, Chaturbhuj D, Portillo VMC, Francomano E, Golden E, Chandrasekhar S, et al. Antibody Responses to
SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva. Pathog Immun. 2021;6(1):116-134. doi:
10.20411/pai.v6i1.441.

23. Castro VT, Chardin H, Amorim Dos Santos J, Barra GB, Castilho GR, Souza PM, etc. Detection of anti-SARS-
CoV-2   salivary   antibodies   in   vaccinated   adults.   Front   Immunol.   2023;14:1296603.   doi:
10.3389/fimmu.2023.1296603.

24. World   Health   Organization.   Clinical   management   of   COVID-19:   living   guideline   (WHO/2019-
nCoV/clinical/2023.2). Available online: https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2023.2
(Accessed May 6, 2025).

25. Faustini SE, Jossi SE, Perez-Toledo M, Shields AM, Allen JD, Watanabe Y, et al. Development of a high-sensitivity
ELISA detecting IgG, IgA and IgM antibodies to the SARS-CoV-2 spike glycoprotein in serum and saliva.
Immunology. 2021;164(1):135-147. doi: 10.1111/imm.13349.

26. Falahi S, Abdoli A, Kenarkoohi A. Claims and reasons about mild COVID-19 in children. New Microbes New
Infect. 2021;41:100864. doi: 10.1016/j.nmni.2021.100864.

27. Brandtzaeg P. Secretory immunity with special reference to the oral cavity. J Oral Microbiol. 2013;5. doi:
10.3402/jom.v5i0.20401.

A

Blood — *P* < .01
Y-axis: IgG anti-Spike BAU/mL (40000, 25000, 10000, 5000, 4000, 3000, 2000, 1500, 1000, 500)
X-axis: non-mRNA (3d), non-mRNA + mRNA (3d)

Saliva — *P* < .01
Y-axis: IgG anti-Spike BAU/mL (3000, 2000, 1000, 500, 400, 300, 200, 100, 45, 30, 15)
X-axis: non-mRNA (3d), non-mRNA + mRNA (3d)

B

Blood — *P* < .0001
Y-axis: IgG anti-Spike BAU/mL (40000, 25000, 10000, 5000, 4000, 3000, 2000, 1500, 1000, 500)
X-axis: 3X, 4X

Saliva — *P* < .01
Y-axis: IgG anti-Spike BAU/mL (3000, 2000, 1000, 500, 400, 300, 200, 100, 45, 30, 15)
X-axis: 3X, 4X

C

Blood — *P* < .0001
Y-axis: IgG anti-Spike BAU/mL (40000, 25000, 10000, 5000, 4000, 3000, 2000, 1500, 1000, 500)
X-axis: ≥51d, ≤50d

Saliva — *P* < .0001
Y-axis: IgG anti-Spike BAU/mL (3000, 2000, 1000, 500, 400, 300, 200, 100, 45, 30, 15)
X-axis: ≥51d, ≤50d

D

Blood — *P* < .0001
Y-axis: IgG anti-Spike BAU/mL (40000, 25000, 10000, 5000, 4000, 3000, 2000, 1500, 1000, 500)
X-axis: Uninfected, Infected

Saliva — *P* < .01
Y-axis: IgG anti-Spike BAU/mL (3000, 2000, 1000, 500, 400, 300, 200, 100, 45, 30, 15)
X-axis: Uninfected, Infected

Figure legends

Figure 1. Systemic and salivary antibody responses against SARS-CoV-2 in vaccinated adults.
Blood and salivary anti-SARS-CoV-2 antibody levels were analyzed in vaccinated adults ($n = 101$) according to: vaccination schedules (A), number of exposures (B), time between last exposure and sample collection (C), SARS-CoV-2 infection (D). IgG anti-spike antibody concentrations (BAU/mL) with geometric means are shown. Dotted line indicates the assay detection limit (4.03 BAU/mL). Subjects with detectable salivary antibodies (white shapes) and those without detectable salivary antibodies (black shapes) are shown. p values were determined by Mann-Whitney test. Samples were assayed in duplicate and the results shown are representative of one of two independent experiments performed. non-mRNA (3d), three doses of non-mRNA-based-vaccines; non-mRNA + mRNA (3d), three doses combining mRNA and non-mRNA-based vaccines.

Figure 2. Comparison of salivary antibody responses against SARS-CoV-2 between vaccinated children and adults. Salivary anti-SARS-CoV-2 antibody levels were compared between vaccinated adults ($n = 101$) and children ($n = 86$) according to: vaccination schedules (A), number of exposures (B), time between last exposure and sample collection (C), SARS-CoV-2 infection (D). IgG anti-spike antibody concentrations (BAU/mL) with geometric means are shown. Dotted line indicates the assay detection limit (4.03 BAU/mL). p values were determined by Mann-Whitney test. Samples were assayed in duplicate and the results shown are representative of one of two independent experiments performed. non-mRNA + mRNA (3d), three doses combining mRNA and non-mRNA-based vaccines; mRNA (3d), three doses of mRNA-based vaccines.

466   **Table 1. Characteristics of children and adults**

	Children (n=86)	Adults (n=101)
General characteristics		
Age, median (range), y	10 (4−17)	46 (27-83)
Sex		
Female, No. (%)	40/86 (47)	71/101 (70)
Male, No. (%)	46/86 (53)	30/101 (30)
COVID-19 history		
Uninfected, No. (%)	35/86 (41)	50/101 (49)
Confirmed past SARS-CoV-2 infection, No. (%)	14/86 (16)	45/101 (45)
Household contacts, No. (%)	37/86 (43)	6/101 (6)
Infected/household contacts with COVID-19 compatible symptoms, No. (%)	30/51 (59)	44/51 (86)
Infected/household contacts exposed to pre-Omicron variants	15/51 (29)	14/51 (27)
Infected/household contacts exposed to Omicron variant	36/51 (71)	37/51 (73)
Vaccination schedules non-mRNA-based		
BBIBP-CorV x 2, No. (%)	46/86 (53)	−
BBIBP-CorV x 2 + ChAdOx1 nCoV-19 x 1, No. (%)	−	62/101 (61)
Sputnik V x 2 + ChAdOx1 nCoV-19 x 1, No. (%)	−	8/101 (8)
ChAdOx1 nCoV-19 x 3, No. (%)	−	4/101 (4)
Vaccination schedules mRNA-based		
BNT162b2 mRNA x 2, No. (%)	5/86 (6)	−
mRNA-1273 x 2, No. (%)	1/86 (1)	−
BNT162b2 mRNA x 3, No. (%)	17/86 (20)	−
BNT162b2 mRNA x 2 + mRNA-1273 x 1, No. (%)	4/86(5)	−
BBIBP-CorV x 2 + BNT162b2 mRNA x1, No. (%)	11/86 (13)	7/101 (7)
BBIBP-CorV x 2 + mRNA-1273 x 1, No. (%)	2/86 (2)	−
Sputnik V x 2 + BNT162b2 mRNA x1, No. (%)	−	5/101 (5)
ChAdOx1 nCoV-19 x 2+ BNT162b2 mRNA x1, No. (%)	−	3/101 (3)
Sputnik V x 1 + mRNA-1273 x 2, No. (%)	−	12/101 (12)
Number of antigen exposures		
Two vaccine doses (2X), No. (%)	23/86 (27)	−
Two vaccine doses plus one infection/household contact exposure (3X), No. (%)	27/86 (31)	−
Three vaccine doses (3X), No. (%)	12/86 (14)	46/101 (46)
Two vaccine doses plus two household contact exposures (4X), No. (%)	2/86 (2)	−
Three vaccine doses plus one infection/household contact exposures (4X), No. (%)	22/86 (26)	55/101 (54)
Time from last antigen exposure and sample collection, median (range), days	77 (21−270)	50 (21-234)
Time from last antigen exposure and sample collection, median (range), days	58 (21-270)	

469   BBIBP-CorV (Sinopharm); BNT162b2 mRNA (Pfizer–BioNTech); mRNA-1273 (Moderna).